Michael Davidian, MD
Internal Medicine · Omaha, NENPI 1780780163
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by AstraZeneca at 25.2% of the total. Reporting peaked in 2019 at $2,964 and has fallen 98.9% since, to $33 in 2025. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$875
- Sanofi-aventis U.S. LLC$799
- Amgen$733
- Bayer$443
- Novo Nordisk$400
- plus $4K from 35 others
What the payments were for
- Food & beverage$9,125100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,140 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $38,052 |
| XareltoRivaroxaban | 26 | $29,669 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,826 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $20,107 |
| JanuviaSitagliptin Phosphate | 14 | $16,436 |
| JardianceEmpagliflozin | 13 | $13,680 |
| FarxigaDapagliflozin Propanediol | 20 | $13,203 |
| MyrbetriqMirabegron | 19 | $9,333 |
| TradjentaLinagliptin | 12 | $6,705 |
| VascepaIcosapent Ethyl | 11 | $5,876 |
| PancreazeLipase/Protease/Amylase | 13 | $3,794 |
| Atorvastatin Calcium | 374 | $2,880 |
| Nebivolol Hcl | 38 | $2,490 |
| SynthroidLevothyroxine Sodium | 20 | $2,032 |
| Bumetanide | 40 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $194 | $38,05250 claims |
| Johnson & JohnsonXarelto | $200 | $29,66926 claims |
| GSKTrelegy Ellipta | $163 | $26,82628 claims |
| Boehringer IngelheimJardiance, Tradjenta | $235 | $20,38525 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $799 | $20,10714 claims |
| MerckJanuvia | $55 | $16,43614 claims |
| AstraZenecaFarxiga | $2,305 | $13,20320 claims |
| Astellas Pharma US IncMyrbetriq | $199 | $9,33319 claims |
| AbbVieSynthroid | $196 | $2,03220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Ali NayfehOmaha$12K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Joel MichalskiOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.